drugset / Trial / NCT01822925
Study of DA-9801 to Treat Diabetic Neuropathy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the effectiveness of DA-9801 at 300mg, 600mg, 900mg and placebo, in reducing pain in subjects with diabetic neuropathic pain compared to their baseline values.
Timeline
- Start
- 2013-11
- Primary completion
- 2015-01
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DA-9801 | Unknown | 100 mg | — |
| Subject | DA-9801 | Unknown | 200 mg | — |
| Subject | DA-9801 | Unknown | 300 mg | — |